• October 23, 2021

Ajinomoto Bio-Pharma Services and DNDi Partner to Develop Critical Immunomodulator for Cutaneous Leishmaniasis Therapeutic

  • September 29, 2020

Ajinomoto Bio-Pharma Services and DNDi Partner to Develop Critical Immunomodulator for Cutaneous Leishmaniasis Therapeutic

Japan, September 29, 2020. Ajinomoto Bio-Pharma Services (“Aji Bio-Pharma”), a leading provider of biopharmaceutical contract development and manufacturing services, is pleased to announce a strategic supply partnership with the Drugs for Neglected Disease Initiative (DNDi), a collaborative, patients’ needs-driven, non-profit drug research and development organization that is developing new treatments…
Live Updates COVID-19 CASES